您现在的位置: 首页> 研究主题> 杂合子丢失

杂合子丢失

杂合子丢失的相关文献在1992年到2019年内共计78篇,主要集中在肿瘤学、基础医学、临床医学 等领域,其中期刊论文78篇、专利文献4923篇;相关期刊44种,包括中华病理学杂志、中华检验医学杂志、中华胃肠外科杂志等; 杂合子丢失的相关文献由346位作者贡献,包括丛文铭、冼志红、刘彤华等。

杂合子丢失—发文量

期刊论文>

论文:78 占比:1.56%

专利文献>

论文:4923 占比:98.44%

总计:5001篇

杂合子丢失—发文趋势图

杂合子丢失

-研究学者

  • 丛文铭
  • 冼志红
  • 刘彤华
  • 卞留贯
  • 吴孟超
  • 周崇治
  • 张树辉
  • 彭志海
  • 沈建康
  • 贺林
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 谢耀盛; 季伟丹; 李阳阳; 金艳慧; 杨丽红; 程晓丽; 王明山
    • 摘要: 目的 对一个新的FGG基因杂合缺失突变导致异常纤维蛋白原血症家系进行表型和基因突变分析,探讨其分子发病机制.方法 收集2016年4月来温州医科大学附属第一医院就诊的先证者临床资料及其家系成员(共3代5人),采用凝固法检测血浆纤维蛋白原活性(Fg:C)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT);免疫比浊法检测纤维蛋白原抗原(Fg:Ag)、D-二聚体(D-D)和纤维蛋白(原)降解产物(FDPs)含量;抽提先证者及其家系成员外周血的基因组DNA,采用PCR扩增先证者纤维蛋白原的FGA、FGB及FGG基因所有外显子和侧翼序列,以及家系成员相应的突变位点区域,产物纯化后直接测序,同时采用克隆测序及非变性聚丙烯酰胺凝胶电泳-银染色进一步验证;用ClustalX-2.1-win软件分析突变位点基因的保守性,并采用Pymol软件分析突变前后蛋白质空间结构及分子间作用力的改变.结果 先证者Fg:C明显下降,而Fg:Ag含量正常,分别为0.30 g/L和2.00 g/L(参考范围均为2.00~4.00 g/L);母亲及外婆Fg:C和Fg:Ag分别为0.42 g/L、2.09 g/L及0.47 g/L和2.42 g/L.基因分析发现先证者FGG基因8号外显子存在c.944_c.952 delCCTTTGATG杂合缺失突变,导致氨基酸289_291delAla,Phe,Asp,其母亲和外婆同样携带此突变,父亲和外公为正常野生型.同源性分析表明Ala289,Phe290,Asp291残基在同源物种间高度保守;蛋白模型分析发现在野生型FGG蛋白质中,Ala289分别与Gly287、Gly292及Thr371形成3个氢键,Phe290分别与Tyr262、Tyr278、His307及Asn308形成4个氢键,Asp291分别与Asp288及Lys302形成2个氢键,当Ala289、Phe290和Asp291发生缺失突变后,原有的氢键连接全部消失.结论 本研究发现了纤维蛋白原γ链289_291delAla,Phe,Asp杂合缺失突变会引起Fg分子空间结构重排,降低了结构稳定性,其与该家系引起异常纤维蛋白原血症有关.(中华检验医学杂志,2018, 41:305-311)%Objective To analyze the phenotype and genotype of inherited dysfibrinogenemia pedigree associated with a novel heterozygous and deletion mutation in the FGG gene,and to investigate its molecular mechanism.Methods The clinical data were collected from the proband found at our hospital and her family members in April 2016.The activity plasma fibrinogen(Fg:C), activated partial thromboplastin time(APTT),prothrombin time(PT), thrombin time(TT)were detected by coagulation method and the antigen plasma fibrinogen(Fg:Ag), D-Dimer(D-D), fibrinogen degradation products (FDPs)were analyzed by immunoturbidimetry method.All of the exons and exon-intron boundaries of the genes of FGA, FGB and FGG with the fibrinogen(Fg)were amplified by PCR and followed by direct sequencing.And further verification were performed by cloning sequence and non-denatured polyacrylamide gel electrophoresis and silver staining.The conservatism of mutated gene locus were analyzed by ClustalX-2.1-win.The change of the protein spatial structure and the intermolecular forces with mutation were analyzed by Pymol.Results The Fg:C of the proband was significantly reduced(0.30 g/L)and the Fg:Ag of the proband was normal(2.00 g/L).Their Fg:C were both significantly reduced and the Fg:Ag were both normal(0.42 g/L,2.09 g/L & 0.47 g/L,2.42 g/L, respectively), these were found in her mother and grandma.Genetic analysis revealed a novel heterozygous and deletion mutation with c.944 _c.952 delCCTTTGATG in exon 8 of FGG gene in the proband,predicting a heterozygous 289_291delAla,Phe,Asp mutation.The same mutations were carried by her mother and grandma, but her father and grandpa were normal.Homology analysis indicated that the Ala 289,Phe290 and Asp291 were maintained highly conservative in homogenous species.Protein model analysis found that the original hydrogen bonds were disappeared when the deletion mutation happened with the Ala 289,Phe290 and Asp291.Conclusion The heterozygous and deletion mutation with 289_291delAla,Phe,Asp in the γchain of fibrinogen were identified that could cause the rearrangement of the Fg molecular space structure and the reduction of the structure stability,so the mutation probably underly the dysfibrinogenemia in this pedigree.(Chin J Lab Med,2018, 41:305-311)
    • 刘志梅; 贾鑫磊; 曾健生; 钱素云; 方方; 丁昌红; 张炜华; 邓劼; 陈春红; 王旭; 刘珺; 李峥
    • 摘要: Objective To investigate the clinical and genetic features of congenital myasthenia syndrome with episodic apnea (CMS-EA) caused by gene mutation of choline acetyltransferase (CHAT)Methods The clinical data of 2 patients with congenital myasthenia syndrome were collected,and both were diagnosed from 2013 to 2015 in Beijing Children's Hospital,Capital Medical University.The clinical features and gene mutation characteristics were analyzed,and the patients were followed-up for therapeutic efficacy.Results The two patients (case 1 and case 2) had the onset soon after birth and at 3 months after birth respectively.The two patients were admitted to the PICU due to dyspnea,cyanotic episodes that required intubation.The patients had repeated apnea and became ventilator dependent.Case 1 died due to refusal of any treatment.Case 2 had a tracheotomy,and gradually weaned from ventilator after using pyridostigmine.The hospitalization of case 2 lasted 162 days.Case 2 was followed up to the age of 3 years and 4 months,and was extubated and was maintained on oral neostigmine but still had fluctuating ptosis and minor physical and mental retardation.Both cases were negative for anti-AChR,anti-acetylcholinesterase,anti-MuSK antibodies.Neostigmine test was negative in case 1 and suspiciously positive in case 2.Low-frequency repetitive nerve stimulation testing of case 2 was negative.Cranial MRI scans of both cases showed brain atrophy-like change.Genetic testing showed compound heterozygous deletions (exon 4,5,6) and pathogenic variant c.914T>C (p.I305T) in CHAT in case 1,compound heterozygous variants c.1007T>C (p.I336T) and c.64C>T (p.Q22X) in CHAT in case 2.To our knowledge,compound heterozygous deletions (exon 4,5,6) and p.Q22X were novel,previously unreported variants.Conclusion CMS-EA usually presents at birth or in the neonatal period with hypotonia,ptosis,dysphagia due to severe bulbar weakness,and respiratory insufficiency with cyanosis and apnea.Early treatment with pyridostigmine is helpful to the improvement of clinical symptoms and prognosis.%目的 探讨胆碱乙酰基转移酶(CHAT)基因突变导致的先天性肌无力综合征伴发作性呼吸暂停(CMS-EA)的临床及遗传学特征.方法 回顾性分析首都医科大学附属北京儿童医院2013年9月、2015年2月收治的2例CMS-EA家系的病例资料,分析其临床特征和基因突变特点,并进行随访.结果 2例患儿分别于生后和3个月余发病,均因呼吸困难、青紫发作气管插管下收住儿童重症监护病房,反复呼吸暂停,不能脱离呼吸机,例1患儿放弃治疗后死亡,例2给予气管切开及溴吡斯的明口服,住院162 d携带气管套管出院,随访患儿至3岁4个月,口服溴吡斯的明,已拔除气管套管,仍有波动性眼睑下垂,程度减轻,智体力发育略落后于同龄儿.2例患儿抗乙酰胆碱受体抗体、抗乙酰胆碱酯酶抗体、抗骨骼肌受体酪氨酸肌酶抗体均阴性;新斯的明试验阴性及可疑阳性各1例;低频神经重复电刺激未见特征性改变;头颅磁共振成像均提示脑萎缩样改变.2例均发现CHAT基因突变,例1为外显子4、5、6杂合缺失和p.I305T复合杂合突变,例2为p.1336T和p.Q22X复合杂合突变,其中,外显子4、5、6杂合缺失和p.Q22X为未报道的新突变.结论 CMS-EA通常表现为自新生儿期或婴儿期起病的肌张力低下、肌无力、发作性眼睑下垂、喂养困难、伴呼吸暂停的呼吸困难,溴吡斯的明治疗有效,早期应用有助于改善临床症状和预后.
    • 高素青; 金士正; 何柳媚; 李桢; 邓志辉; 洪文旭
    • 摘要: Objective To investigate the characteristics and causes of allelic drop-out at the autosomal short tandem repeat (STR) loci,and to explore the confirmation strategy of suspected mutations at the STR loci alleles in paternity.Methods From January to June 2017,nine family members from 3 families of three-banded patterns at Shenzhen Blood Center were selected as subjects.Subject inclusion criteria:subjects' initial test results of the STR loci alleles did not conform to the Mendels laws of genetics,which were suspected allelic drop-out at STR loci.GlobalFilerTM Express kits from ABI,USA were initially used to detect genotype of 21 autosomal STR loci alleles from all blood spot samples.All blood spot samples suspected for having allelic drop-out were verified with the PowerPlex(R) 21 kits from Promega,USA.Supplemental experiment was used human leukocyte antigen (HLA)-A/-B/-C/-DR/-DQB1 loci genotype test results with PCR-sequence-based typing (SBT) method,and then the haplotype of the subjects was deduced by the family analysis to complete the individual identification verification.This study met the requirements of World Medical Association Declaration of Helsinki revised in 2013.Informed consent was obtained from every subject.Results ① In this study,the allelic drop-out in 6 subjects occurred in 3 STRloci of CSF1PO,D1S165 and TH01,respectively,and the number of mutation steps were different.These allelic drop-out could be either paternal or maternal.② In family 1,the initial test result of CSF1PO locus was homozygous in both mother and child.The verification test result of CSF1PO locus was heterozygous,and allelic drop 10-locus were confirmed.③ In family 2,the initial test result of D1S165 locus was homozygous in both child and father.The verification test result of D1S165 locus was heterozygous,and allelic drop-out 16-locus was confirmed.④ In family 3,the initial test result of TH01 locus was homozygous in both the mother and child.The verification test result of TH01 locus was heterozygous,and allelic drop-out 9-locus was confirmed.⑤ Twelve HLA-A/-B/-C/-DRB1/-DQB1 loci haplotypes were detected in the DNA samples of 9 subjects,and the HLA locus haplotypes were detected in accordance with Mendels laws of genetics.Conclusions For the suspected STR allelic mutations in STR composite amplification,a single test has the possibility of allelic drop-out risk.Different kits could be used to verify the authenticity of allele mutations,and more reliable results could be obtained.%目的 探讨常染色体短串联重复序列(STR)基因座复合扩增等位基因丢失现象的特征和原因,以及亲子鉴定中STR基因座等位基因疑似突变的确认策略.方法 选择2017年1月至6月,于深圳市血液中心接受三联体亲子鉴定的3个家庭的9例家庭成员为研究对象.研究对象纳入标准:STR基因座等位基因初检结果不符合孟德尔遗传规律,疑为STR基因座等位基因丢失者.采用美国ABI公司生产的GlobalFilerTM Express试剂盒对受试者血斑片样本的21个常染色体STR基因座等位基因进行分型.采用美国Promega公司生产的PowerPlex(R) 21复合扩增系统对受试者血斑片样本的STR等位基因分型结果进行验证.采用PCR-直接测序(SBT)法,检测受试者DNA样本人类白细胞抗原(HLA)-A/-B/-C/-DR/-DQB1基因座等位基因,并且对受试者HLA基因座单倍型进行分型,作为个体识别的补充验证.本研究所遵循的程序符合2013年修订的《世界医学协会赫尔辛基宣言》,并且与受试者或其监护人签订知情同意书.结果 ①本研究3个家庭的三联体亲子鉴定中,6例受试者丢失的等位基因分别发生在STR的3个基因座CSF1PO、D1S165和TH01,并且突变步数均不相同.上述丢失的等位基因,既可能为父源性,亦可能为母源性.②家庭1中,对母亲和孩子的CSF1PO基因座等位基因分型的初检结果显示,等位基因均为纯合子;验证结果显示,等位基因均为杂合子;二者的CSF1PO基因座等位基因初检结果均丢失等位基因10.③家庭2中,对父亲和孩子的D1S1656基因座等位基因分型的初检结果显示,等位基因均为纯合子;验证结果显示,等位基因均为杂合子;二者的D1S1656基因座等位基因初检结果均丢失等位基因16.④家庭3中,对母亲和孩子的TH01基因座等位基因分型的初检结果显示,等位基因均为纯合子;验证结果显示,等位基因均为杂合子;二者的TH01基因座等位基因初检结果均丢失等位基因9.⑤于3个家庭的9例受试者DNA标本中,共检出12种HLA-A/-B/-C/-DRB1/-DQB1基因座单倍型,并且HLA基因座单倍型遗传方式符合孟德尔遗传规律.结论 对于疑似存在STR等位基因突变的STR基因座复合扩增中,采取单一的检测方法,可能存在漏检等位基因的风险,采用不同试剂盒进行验证其等位基因突变的真实性,能获得更加可靠的鉴定结果.
    • 张鲁洲; 王政禄; 王玉亮; 郑虹
    • 摘要: Objective To determine the tumor clonal origin of diffuse hepatocellular carcinoma (D-HCC) and clinical outcome after liver transplantation. Methods Fourteen D-HCC patients who underwent liver transplantation in the Tianjin First Central Hospital between August 2004 to November 2012 were evaluated retrospectively. Their clinical characteristics and data of disease-free survival postoperatively were gathered. Twelve loss of heterozygosity sites (LOH) on high frequency microsatellite were selected. The tumor clonal origin of D-HCC was assessed by the means of PCR-SSCP. Results Of 14 D-HCC patients, intrahepatic metastasis (IM) occurred in 11 cases (11/14), and IM with multicentric occurrence (MO) occurred in 3 cases (3/14). The disease-free survival time was 4.5 to 37.4 months, and the median time was 8.7 months. Conclusion The most frequent tumor clonal origin of D-HCC was IM. Liver transplantation may be the effective treatment for D-HCC.%目的 探究弥漫型肝细胞癌(D-HCC)的肿瘤克隆起源方式及其行肝移植治疗的预后.方法 选取2004年8月—2012年11月天津市第一中心医院肝移植治疗的14例D-HCC患者,收集患者一般资料及术后无瘤生存资料.选取12个高频肝癌微卫星杂合性缺失(LOH)位点,通过聚合酶链反应-单链构象多态性(PCR-SSCP)评估D-HCC的肿瘤克隆起源方式.结果 14例D-HCC患者中,有11例单中心克隆起源(IM),3例单中心伴多中心克隆起源(IM+MO).术后无瘤生存时间为4.5~37.4个月,无瘤生存中位时间为8.7个月.结论 D-HCC的肿瘤克隆起源方式以IM为主,肝移植可能是较为有效的治疗手段.
    • 姚坤; 段泽君; 胡泽良; 边宇; 齐雪岭
    • 摘要: 目的 观察少突胶质细胞起源肿瘤及少突-星形细胞起源肿瘤1p/19q杂合性缺失与人IDH1-R132H突变蛋白表达的相关性,探索预测少突胶质细胞起源肿瘤及少突-星形细胞起源肿瘤化疗敏感性的分子标志物.方法 选择病理学诊断为各类型和级别的少突胶质细胞起源肿瘤38例及少突-星形细胞起源肿瘤37例,共75例,采用荧光原位杂交方法检测1p/19q杂合性缺失,免疫组织化学法检测其IDH1-R132H突变蛋白表达.结果 75例少突胶质细胞起源肿瘤及少突-星形细胞起源肿瘤1p/19q杂合性缺失为37例(37/75,49.3%),其中34例1p和19q同时发生缺失,1p缺失与19q缺失二者密切相关(P<0.01).在少突胶质细胞瘤(WHOⅡ级)中,1p/19q杂合性缺失检出率比间变性少突胶质细胞瘤(WHOⅢ级)高,但差异无统计学意义(P>0.05).少突胶质细胞起源肿瘤(WHOⅡ级和WHOⅢ级)中1p/19q杂合性缺失率高于少突-星形细胞起源肿瘤(WHOⅡ级和WHOⅢ级,P <0.05).而且少突胶质细胞起源肿瘤中1p/19q杂合性缺失均为联合缺失,1p和19q的单独缺失仅发生在少突-星形细胞起源肿瘤中.在75例中51例(68.0%)少突胶质细胞起源肿瘤及少突-星形细胞起源肿瘤出现IDH1-R132H突变蛋白表达.少突胶质细胞起源肿瘤IDH1-R132H突变蛋白检测阳性率高于少突-星形细胞起源肿瘤.而且少突胶质细胞起源肿瘤及少突-星形细胞起源肿瘤中,IDH1-R132H突变蛋白阳性表达与1p/19q杂合性缺失均有明显相关性(P<0.05).结论 IDH1-R132H突变蛋白表达与1p/19q杂合性缺失有明显相关性,IDH1-R132H蛋白是预测少突胶质细胞起源肿瘤及少突-星形细胞起源肿瘤1p/19q是否杂合性缺失的潜在分子标志物.%Objective To correlate the presence of chromosome 1p/19q deletion with the expression of R132H mutant IDH1 status in oligodendroglial tumors,and to explore molecular markers for predicting chemosensitivity of oligodendroglial tumors.Methods The study included 75 oligodendroglial tumors (38 oligodendrogliomas and 37 oligoastrocytomas).Immunohistochemistry was used to detect the expression of R132H mutant IDH1 protein,and fluorescence in situ hybridization (FISH) was employed to detect 1p/19q deletion.Results Deletion of chromosome 1p and/or 19q was detected in 37 cases(37/75,49.3%),among which co-deletion of 1p and 19q was seen in 34 cases (closely correlated,P < 0.01).Oligodendrogliomas WHO Ⅱ had a slightly higher deletion rate than oligodendrogliomas WHO Ⅲ,although without statistical significance.Oligodendrogliomas WHO Ⅱ and WHO Ⅲ had a significantly higher deletion rate of chromosome 1p/19q than oligoastrocytomas WHO Ⅱ and WHO Ⅲ (P <0.05).While combined loss of 1p/19q was always detected in oligodendrogliomas when FISH was positive,isolated 1p or 19q deletion was only found in oligoastrocytomas.The expression of R132H mutant IDH1 was detected in 51 of 75 cases (68.0%),in which oligodendrogliomas had a higher positive rate than oligoastrocytomas.Statistical analysis demonstrated a significant correlation between the expression of R132H mutant IDH1 protein and the presence of combined 1p/19q deletion in oligodendrogliomas (P < 0.05).Conclusions A significant correlation was observed between the expression of R132H mutant protein and 1p/19q LOH.Expression of 132H mutant IDH1 protein is the potential biomarker for predicating the presence of 1p/19q deletion in oligodendrogliomas.
    • 张海勇; 危晓莉; 王玲玲; 张布衣; 赵仲生; 吕燕博; 姚根有
    • 摘要: Objective To study the possible clonal origin of neuroendocrine cells in colorectal adenocarcinoma.Methods Twenty-six microsatellite loci were screened using laser capture microdissection,DNA extraction and whole genome amplification.Microsatellite instability (MSI) and loss of heterozygosity (LOH) in adenocarcinoma cells and neuroendocrine cells amongst 30 cases of colorectal carcinoma with neuroendocrine differentiation were detected using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP)-silver staining.The mutation status of p53 was evaluated by PCR-sequencing.The clonal origin of neuroendocrine cells in colorectal adenocarcinoma was determined.Results Amongst the 30 cases studied,the prevalence of MSI was 16.9% while that of LOH was 8.5%.The rate showed no statistically significant difference between adenocarcinoma cells and neuroendocrine cells.In 6 cases,the microsatellite alteration was entirely consistent.In 23 cases,the rate of microsatellite alteration consistency was greater than that of inconsistency.In 1 case,the consistency and inconsistency rates were identical.There was statistically significant difference between consistency and inconsistency of microsatellite alteration.The prevalence of p53 mutation was 16.7% which was the same for both adenocarcinoma cells and neuroendocrine cells.Conclusions Adenocarcinoma cells and neuroendocrine cells in colorectal adenocarcinoma with neuroendocrine differentiation have similar biologic changes.It is likely that they are of identical origin.%目的 通过检测结直肠腺癌中神经内分泌(NE)细胞微卫星改变和p53基因突变,探讨结直肠腺癌中NE细胞的克隆性起源.方法 采用激光捕获显微切割(LCM)技术,应用DNA抽提和全基因组扩增,在全基因组范围内选取26个微卫星位点,使用聚合酶链反应-单链构象多态性(PCR-SSCP)-银染色检测30例伴NE分化的结直肠腺癌中腺癌细胞和NE细胞的微卫星不稳定(MSI)、杂合性缺失(LOH)改变情况,联合PCR测序检测p53基因突变发生情况.结果 30例样本MSI总发生率为16.9%,LOH总发生率为8.5%,腺癌细胞与NE细胞的MSI和LOH发生率差异无统计学意义.30例样本中6例微卫星改变完全一致,23例微卫星改变一致性大于不一致性,1例微卫星改变一致性与不一致性相同.微卫星改变一致性与不一致性的差异有统计学意义(t=11.138,P=0.000).p53基因突变发生率为16.7%,腺癌细胞与NE细胞发生一致性改变.结论 结直肠腺癌中腺癌细胞与NE细胞具有相似的微卫星改变和完全一致的p53基因突变,推测两种细胞起源具有一致性.
    • 李化梅; 李龙萍; 苏俊; 喻安孝; 邓飞
    • 摘要: Objective To evaluate the role of bcl-2 gene rearrangement and microsatellite DNA alteration in pathogenesis of B-cell lymphoma,and to discuss the relationship of bcl-2/IgH gene rearrangement with microsatellite instability and loss of heterozygosity.Methods Thirty-seven cases of B-cell lymphoma were studied for bcl-2 gene rearrangement with nested-PCR method;two microsatellite makers located at chromosome 14 were selected to detected microsatellite alterations (MSI and LOH)by single-strand conformation polymorphism (PCR-SSCP).Results Rearrangement rate of bcl-2 gene was 24.3 % (9/37) in 37 B-cell lymphoma cases; Positive rate of MSI was 48.6% (18/37),while positive rate of LOH was 40.5% (15/37).The high frequency of MSI/LOH was at locus of D14S65(29.7%,27%).Bcl-2/IgH gene rearrangement was correlated with MSI at D14S65 (P <0.05),while no correlation was found between MSI or LOH and bcl-2/IgH gene rearrangement at D14S45 (P > 0.05).Conclusion D14S65 is sensitive microsatellite loci in B-cell lymphoma,bcl-2/IgH gene rearrangement and MSI might play a role in pathogenesis of B-cell lymphoma.%目的 研究bcl-2/IgH基因重排与微卫星DNA改变在B细胞淋巴瘤发生发展中的作用以及bcl-2/IgH基因重排与微卫星不稳定和杂合性缺失之间的关系.方法 应用巢式PCR方法检测bcl-2/IgH基因重排;选取14号染色体上2个微卫星多态性标记,采用聚合酶链反应-单链构象多态性分析法(PCR-SSCP)检测37例B细胞淋巴瘤中微卫星不稳定和杂合性缺失.结果 37例B细胞淋巴瘤中,bcl-2/IgH基因重排频率为24.3% (9/37);微卫星不稳定发生率为48.6% (18/37),杂合性缺失发生率为40.5% (15/37),其中D14S65位点微卫星不稳定和杂合性缺失频率较高,分别为29.7%(11/37)和27%(10/37).经统计学分析结果显示:D14S65位点bcl-2/IgH基因重排与微卫星不稳定有关(P<0.05),与杂合性缺失无关(P>0.05);但D14S45位点bcl-2/IgH基因重排与微卫星不稳定和杂合性缺失无关(P>0.05).结论 D14S65是B细胞淋巴瘤中敏感的检测位点,bcl-2/IgH基因重排和微卫星不稳定性可能共同导致B细胞淋巴瘤的发生.
    • 曹建; 孙萍
    • 摘要: For stage Ⅱ colon cancer patients after surgery,the benefit of adjuvant chemotherapy remains controversial.Several studies indicate that the patients with high-risk stage Ⅱ colon cancer can benefit from adjuvant chemotherapy after surgery.According to the clinical and pathological features,the stage Ⅱcolon cancer patients including T4 lesion,perforation,peritumoral lymphovascular invasion can benefit from the adjuvant chemotherapy of oxaliplatin.In the horizontal of molecular and genetic levels,the stage Ⅱ colon cancer patients can express high microsatellite instability (MSI-H) and cannot benefit from the chemotherapy of Fluorouracil.The guiding functions of 18q loss of heterozygosity (18q LOH),Cx43 and gene expression profiling in adjuvant chemotherapy are still unclear,and need further study.%Ⅱ期结肠癌术后是否需行辅助化疗,目前尚存争议.有研究表明,高危Ⅱ期结肠癌能从术后辅助化疗中获益.在临床病理特征方面,T4期、有穿孔和肿瘤周围淋巴管或血管浸润等的Ⅱ期结肠癌患者能从含有奥沙利铂的辅助化疗中获益;在基因分子水平方面,Ⅱ期结肠癌高微卫星不稳定性(MSI-H)表达较多,且不能从氟尿嘧啶化疗中获益,而染色体18q杂合子丢失(18q LOH)、Cx43及基因表达谱等在辅助化疗中的指导作用尚无定论,需进一步研究.
    • 林瀛; 陈小岩; 何毅辉; 晋龙; 俞训彬
    • 摘要: 目的 探讨染色体1p36可能存在的与非特殊类型乳腺浸润性导管癌发生、发展有关的肿瘤抑制基因,为发现和定位肿瘤抑制基因提供线索和热点位点.方法 选取1号染色体8个微卫星多态位点标志物,采用新鲜和石蜡组织基因组DNA抽提-PCR扩增-变性聚丙烯酰胺凝胶垂直电泳-银染法-全自动凝胶成像系统分析,检测80例浸润性导管癌及癌旁正常组织基因组DNA的杂合性缺失(LOH)频率.应用x2检验对实验结果进行综合分析.结果 80例浸润性导管癌中有45例(56.3%)至少在一个位点出现LOH,其中D1S1310微卫星位点频率最高,为35.7%(25/70).结论 乳腺浸润性导管癌染色体1p36发生高频率LOH,提示1p36.23 ~ 33区间可能存在与乳腺癌发生、发展有关的抑癌基因.%Objective The study of loss of heterozygosity (LOH) on chromosome 1p36 was performed to locate the deletion areas probably harboring tumor suppressor genes in invasive ductal breast carcinoma not otherwise specified (IDC NOS).Methods Eighty paired breast cancerormal tissue DNA samples were examined for LOH on chromosome lp36 using eight polymorphic microsatellite (MS) loci.The PCR products were electrophoresed on 8% denatured polyacrylamide gel and stained using silver staining.Finally,the data were analysed and compared with the clinicopathological parameters using statistical analysis.Results In 80 IDC NOS,LOH was identified in 45 cases (56.3 %) at least in one MS locus.MS locus D1S1310 showed the highest rate of LOH [35.7% (25/70)].Conclusion Chromosome 1p36 might be the highly deleted region.The results of this study indicate that the chromosomal regions 1p36.23-33 might contain tumor suppressor genes associated with human breast carcinomas.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号